1075715-65-9

Downstream Products

• 1202478-38-3 8-hydroxy-3-methyl-1-oxo-2-pyridin-3-yl-1,2-dihydro-isoquinoline-4-carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 
• 1075715-82-0 2-(1-{[(S)-Cyclopropyl-(3-fluoro-phenyl)-methyl]-carbamoyl}-2-oxo-propyl)-6-fluoro-benzoic acid 
• 1215093-44-9 8-fluoro-3-methyl-1-oxo-2-propyl-1,2-dihydro-isoquinoline-4-carboxylic acid [(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amide 
• 1075715-76-2 4-Acetyl-3-{[(S)-cyclopropyl-(3-fluoro-phenyl)-methyl]-amino}-8-fluoro-isochromen-1-one 

Relevant academic research and scientific papers

ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS

The invention relates to isoquinolinone derivatives useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.

ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS

The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.

ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS

Isoquinolone derivatives of the general formula (I) are NK3 antagonists.

ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS

Isoquinolone derivatives of the general formula are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.

ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS

Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.